Suggestions
James Sabry
Global Head, Roche Pharma Partnering at Roche
Professional Background
James Sabry is a highly accomplished executive in the biopharmaceutical industry, currently serving as the Global Head and Executive Vice President of Roche Partnering. In this key role, he leads the dynamic teams from both Roche and Genentech, further solidifying his position as a pivotal figure in global healthcare. As a member of the Roche enlarged Corporate Executive Committee, he plays a crucial role in shaping the strategic direction of the organization, ensuring that Roche remains at the forefront of pharmaceutical innovation.
Before stepping into his current role at Roche, Mr. Sabry held the position of Senior Vice President of Genentech Partnering, where he was instrumental in establishing strategic alliances that propelled the company's drug development programs. His impressive track record also includes serving as the President and CEO of Arete Therapeutics, where he led initiatives aimed at advancing therapeutic solutions for a variety of serious diseases. Additionally, James served as the Chairman of the Board of Directors at Cytokinetics, a cutting-edge biotechnology firm that he co-founded in August 1997, showcasing his entrepreneurial spirit and commitment to innovation in drug discovery.
Moreover, he currently holds a position on the scientific advisory board of Cytokinetics, where he continues to contribute to the company's research and development endeavors. His deep expertise in biopharmaceuticals is complemented by his experience as a faculty member at prestigious institutions such as the University of California, San Francisco, and Harvard Medical School, where he honed his skills in translating cutting-edge research into viable therapeutic solutions.
Education and Achievements
James Sabry's educational background is as illustrious as his professional career. He earned his Doctor of Medicine (M.D.) degree from Queen’s University, where he laid the foundation for his medical expertise. He further advanced his knowledge in neuroscience by obtaining a Ph.D. from the University of California, San Francisco, which equipped him with a profound understanding of the complexities of human biology and disease processes.
His commitment to excellence in medical education led him to undertake a residency in neurology at Harvard Medical School, followed by studies as a post-doctoral fellow in biochemistry at Stanford University. James also holds a Master of Science (M.Sc.) in Biology from the California Institute of Technology (Caltech). This rich academic backdrop has been instrumental in his approach to drug discovery and development, allowing him to identify novel targets and innovative strategies to address serious medical conditions.
In addition to his educational accomplishments, Mr. Sabry has also been recognized for his leadership capabilities and innovative contributions to the field of life sciences. He has held esteemed positions such as a board member of Chugai Pharma and the California Life Sciences Association (CLSA), as well as serving on the Dean’s Council of the Kennedy School of Government at Harvard University. His involvement in these organizations underscores his commitment to advancing the life sciences community.
Achievements
James Sabry's achievements are numerous and impactful, highlighting his dedication to improving healthcare outcomes through innovative drug development initiatives. He has been pivotal in facilitating drug discovery and development alliances that focus on novel biological targets, effectively managing the complexities that arise within human health processes.
Mr. Sabry has made significant contributions to organizations like HopeLab, a non-profit developing forward-thinking technologies for cancer, obesity, and other health challenges, as well as the American Society for Cell Biology, where he served as a council member. His leadership and insights reflect a profound understanding of not only biomedicine but also the socio-economic aspects involved in drug development.
With a keen interest in evolutionary approaches to drug discovery, James emphasizes the need for a nuanced understanding of human biological variations in order to foster effective treatments. This philosophy has guided his career and continues to inform his work at Roche Partnering, where he is actively engaged in exploring cutting-edge research and innovative therapies.
In summary, James Sabry is a dynamic leader with an impressive background in medicine, research, and biopharmaceutical development. His contributions to the life sciences industry are notable not only for their scope but also for their impact on enhancing therapeutic strategies for complex diseases. Through his strategic vision and passion for innovative healthcare solutions, he exemplifies the qualities of a dedicated and forward-thinking leader in the biopharmaceutical sector.
Highlights
We all know that AI has taken over many aspects of our daily lives, but what about drug development?
I remember when one of my colleagues first mentioned AI, it seemed like such a far-off concept to be using in drug development...look where we are today. We know that the path to discovering and developing medicines is filled with challenges. The integration of AI into the drug discovery process can be a true game-changer. Advanced approaches can improve success rates and speed up the development of life-changing therapies.
Let me tell you why I am so thrilled to work with a partner like NVIDIA. As the world changes, we also need to rethink our partnerships in different, out-of-the-box ways. NVIDIA, as a leading tech company, might seem like an unusual partner, but for us, it’s a perfect match. We combine NVIDIA's expertise and cutting-edge technology with our deep understanding of science and our computational capabilities. It's certainly an exciting partnership that could benefit not only health outcomes for patients but also the technology side, applied to develop better medicines, faster.
I am convinced that in the next decade, the potential of AI in healthcare will be beyond what we can imagine. By leveraging its power, we can unravel the complexities of disease biology, predict effective treatments, and design therapies faster than ever before.
Learn more about how these efforts are already making an impact on our work in advancing innovative therapies: https://lnkd.in/gm_h5kBd
#AI #healthcareinnovation #drugdiscovery #partnership
